A Phase 1, Single-Time Blood Sample Collection Study for Pharmacogenomic Characterization of Subjects That Previously Received Namilumab and Participated in the Phase 1 PRIORA Study.

Completed

• Conditions: RA; Rheumatoid arthritis; 10003816

• Registration Number: NL-OMON42614
• Lead Sponsor: Takeda

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 4

Inclusion Criteria

The participant (or, when applicable, the participant*s legally acceptable representative) voluntarily signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.

Exclusion Criteria

-Participants who did not receive namilumab during the PRIORA study.
-Participants without any response time point recorded 4-week after the last dose of namilumab and beyond this time point
-Participants who were excluded from post-hoc analysis due to protocol violations during the previous PRIORA study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p> Number blood samples collected for Genotyping for correlation of RA-suceptible<br /><br>genetic markers with<br /><br>responses</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable.</p><br>